D. Voliotis
About
D. Voliotis is a scholar working on Hepatology, Molecular Biology and Oncology.
According to data from OpenAlex, D. Voliotis has authored 48 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hepatology, 15 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in D. Voliotis's work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Cancer, Lipids, and Metabolism (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). D. Voliotis is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Cancer, Lipids, and Metabolism (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). D. Voliotis collaborates with scholars based in Germany, United States and France. D. Voliotis's co-authors include M. Moscovici, Dirk Strumberg, Josep M. Llovet, Jordi Bruix, Jean‐Luc Raoul, M. E. Scheulen, Vincenzo Mazzaferro, S. Seeber, Heike Richly and Brian Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
In The Last Decade
D. Voliotis
47 papers receiving 2.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| D. Voliotis Germany | 20 | 1.4k | 970 | 953 | 666 | 604 | 48 | 3.0k | ||
| John Kauh United States | 28 | 875 0.6× | 1.0k 1.1× | 1.4k 1.4× | 492 0.7× | 660 1.1× | 106 | 3.0k | ||
| Gerold Meinhardt United States | 27 | 2.8k 2.0× | 1.0k 1.1× | 1.3k 1.4× | 1.2k 1.8× | 725 1.2× | 58 | 4.8k | ||
| 재연 정 | 2 | 2.8k 2.1× | 1.4k 1.5× | 1.2k 1.3× | 984 1.5× | 779 1.3× | 2 | 4.8k | ||
| Heinz‐Josef Klümpen Netherlands | 30 | 838 0.6× | 610 0.6× | 1.6k 1.7× | 369 0.6× | 983 1.6× | 154 | 3.3k | ||
| O. Kisker Germany | 28 | 492 0.4× | 988 1.0× | 2.0k 2.1× | 376 0.6× | 876 1.5× | 43 | 3.3k | ||
| Thomas W. T. Leung Hong Kong | 24 | 2.1k 1.6× | 593 0.6× | 829 0.9× | 531 0.8× | 613 1.0× | 49 | 3.5k | ||
| Heike Richly Germany | 20 | 360 0.3× | 1.1k 1.1× | 1.2k 1.2× | 326 0.5× | 736 1.2× | 56 | 2.4k | ||
| Mohamed Bouattour France | 22 | 1.9k 1.4× | 491 0.5× | 1.5k 1.5× | 620 0.9× | 673 1.1× | 109 | 3.2k | ||
| Tsai‐Shen Yang Taiwan | 11 | 1.3k 1.0× | 557 0.6× | 2.8k 2.9× | 588 0.9× | 1.1k 1.9× | 19 | 3.7k | ||
| Éveline Boucher France | 32 | 2.0k 1.5× | 333 0.3× | 1.3k 1.3× | 369 0.6× | 1.2k 2.0× | 118 | 3.7k |
Countries citing papers authored by D. Voliotis
Since
Specialization
Citations
This map shows the geographic impact of D. Voliotis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Voliotis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Voliotis more than expected).
Fields of papers citing papers by D. Voliotis
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by D. Voliotis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Voliotis. The network helps show where D. Voliotis may publish in the future.
Co-authorship network of co-authors of D. Voliotis
This figure shows the co-authorship network connecting the top 25 collaborators of D. Voliotis. A scholar is included among the top collaborators of D. Voliotis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Voliotis. D. Voliotis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fu, Siqing, Gary Richardson, Tarek Meniawy, et al.. (2021). 562TiP A phase Ib dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer. Annals of Oncology. 32. S618–S618.
2.
Raoul, Jean‐Luc, Jordi Bruix, Tim F. Greten, et al.. (2012). Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology. 56(5). 1080–1088.
3.
Bruix, Jordi, Jean‐Luc Raoul, Morris Sherman, et al.. (2012). Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology. 57(4). 821–829.
4.
Cheng, Ann‐Lii, Zhongzhen Guan, Zhendong Chen, et al.. (2012). Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial. European Journal of Cancer. 48(10). 1452–1465.
5.
Galle, Peter R., Jean‐Frédéric Blanc, Jean‐Luc Van Laethem, et al.. (2008). 994 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND PRIOR ANTI-TUMOR THERAPY: A SUBANALYSIS FROM THE SHARP TRIAL. Journal of Hepatology. 48. S372–S372.
6.
Abou-Alfa, G.K., D. Amadori, Armando Santoro, et al.. (2008). Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?. Journal of Clinical Oncology. 26(15_suppl). 4518–4518.
7.
Llovet, Josep M., Serafino Ricci, Vincenzo Mazzaferro, et al.. (2007). Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 25(18_suppl). LBA1–LBA1.
8.
Strumberg, Dirk, Ahmad Awada, Holger W. Hirte, et al.. (2006). Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. European Journal of Cancer. 42(4). 548–556.
9.
Mross, K., Simone Steinbild, Martin Radtke, et al.. (2006). Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. European Journal of Cancer. 43(1). 55–63.
10.
Zisowsky, Jochen, et al.. (2005). The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anti-Cancer Drugs. 16(2). 129–136.
11.
Larson, Richard A., Eric L. Sievers, Edward A. Stadtmauer, et al.. (2005). Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence. Cancer. 104(7). 1442–1452.
12.
Mross, K., Heike Richly, N. Schleucher, et al.. (2004). A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors. Annals of Oncology. 15(8). 1284–1294.
13.
Steinbild, Simone, Frank Baas, Peter Buss, et al.. (2003). Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 41(12). 618–619.
14.
Richly, Heike, P. Kupsch, M. Grubert, et al.. (2003). A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 41(12). 620–621.
15.
Voliotis, D. & Volker Diehl. (2002). Challenges in treating hematologic malignancies. Seminars in Oncology. 29(3 Suppl 8). 30–39.
16.
Strumberg, Dirk, D. Voliotis, J Moeller, et al.. (2002). Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 40(12). 580–581.
17.
Staib, Peter, B. Lathan, Hans Tesch, et al.. (1998). Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients. Annals of Oncology. 9(2). 221–223.
18.
Schmitz, S., et al.. (1994). Continuous 5-Fluorouracil and Leucovorin as a Second-Line Therapy for Advanced Gastric Carcinoma. Oncology. 51(6). 502–506.
19.
Schmitz, S., Stefan Scheding, D. Voliotis, et al.. (1994). Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood. Annals of Hematology. 69(3). 135–138.
20.
Lindemann, A., K. Höffken, Michael Flaßhove, et al.. (1994). Serum Cytokine Levels in Cancer Patients Treated with Different Schedules of Ultra-Low-Dose Interleukin-2. Journal of Immunotherapy. 15(3). 225–230.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by John Kauh Breakdown of academic impact, for papers by Gerold Meinhardt Breakdown of academic impact, for papers by 재연 정 Breakdown of academic impact, for papers by Heinz‐Josef Klümpen Breakdown of academic impact, for papers by O. Kisker Breakdown of academic impact, for papers by Thomas W. T. Leung Breakdown of academic impact, for papers by Heike Richly Breakdown of academic impact, for papers by Mohamed Bouattour Breakdown of academic impact, for papers by Tsai‐Shen Yang Breakdown of academic impact, for papers by Éveline Boucher